Engineering nanosystems to overcome barriers to cancer diagnosis and treatment

Alhaj‐Suliman, Suhaila O.; Wafa, Emad I.; Salem, Aliasger K.

doi:10.1016/j.addr.2022.114482

Cited by 33 publications

(35 citation statements)

References 291 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The appropriate lipidic, polymeric, and/or inorganic materials can be determined based on their physicochemical, in vitro and in vivo advantages, which have been previously compared by other research groups. [ 122–124 ]…”

Section: Recent Advances Of Ndds For Chemotherapeutic Icd Inducersmentioning

confidence: 99%

See 1 more Smart Citation

Nano Delivery of Chemotherapeutic ICD Inducers for Tumor Immunotherapy

2023

View full text Add to dashboard Cite

Immunogenic cell death (ICD, also known as immunogenic apoptosis) of malignant cells is confirmed to activate the host immune system to prevent, control, and eliminate tumors. Recently, a range of chemotherapeutic drugs have been repurposed as ICD inducers and applied for tumor immunotherapy. However, several hurdles to the widespread application of chemotherapeutic ICD inducers remain, namely poor water solubility, short blood circulation, non‐specific tissue distribution, and severe toxicity. Recent advances in nanotechnology and pharmaceutical formulation foster the development of nano drug delivery systems to tackle the aforementioned hurdles and expedite safe, effective, and specific delivery. This review will describe delivery barriers to chemical ICD inducers and highlight recent nanoformulations for these drugs in tumor immunotherapy.

show abstract

Section: Recent Advances Of Ndds For Chemotherapeutic Icd Inducersmentioning

confidence: 99%

“…determined based on their physicochemical, in vitro and in vivo advantages, which have been previously compared by other research groups. [122][123][124]…”

Section: Othersmentioning

confidence: 99%

Nano Delivery of Chemotherapeutic ICD Inducers for Tumor Immunotherapy

2023

View full text Add to dashboard Cite

show abstract

“…In a nanocarrier therapeutic system, undesired burst release occurs in the physiological environment 106 , which requires the biochemical design of a passivation layer on the particle surface to restrict drug leakage. The other challenge is the limitation of complete release (70-90%) either by light, pH, enzyme reaction, or magnetic waves in the controlled release nanocarrier system 107 , 108 and thus would suffer from an insufficient drug dose in the lesion with practical clinical trial applications. Most importantly, the surface of RT-activated nanoparticles can simply modify the biomolecules 109 to improve the water dispersity and increase the targeting rate without concern for the retention of the chemical drugs on the surface or in the core area structures by a complicated layer-by-layer coating process 106 .…”

Section: The Benefits Of Nanotechnology In Enhancing Anticancer Effec...mentioning

confidence: 99%

Nanoparticles augment the therapeutic window of RT and immunotherapy for treating cancers: pivotal role of autophagy

Wu¹,

Chen²,

Chiu³

et al. 2023

Theranostics

View full text Add to dashboard Cite

Immunotherapies are now emerging as an efficient anticancer therapeutic strategy. Cancer immunotherapy utilizes the host's immune system to fight against cancer cells and has gained increasing interest due to its durable efficacy and low toxicity compared to traditional antitumor treatments, such as chemotherapy and radiotherapy (RT). Although the combination of RT and immunotherapy has drawn extensive attention in the clinical setting, the overall response rates are still low. Therefore, strategies for further improvement are urgently needed. Nanotechnology has been used in cancer immunotherapy and RT to target not only cancer cells but also the tumor microenvironment (TME), thereby helping to generate a long-term immune response. Nanomaterials can be an effective delivery system and a strong autophagy inducer, with the ability to elevate autophagy to very high levels. Interestingly, autophagy could play a critical role in optimal immune function, mediating cell-extrinsic homeostatic effects through the regulation of danger signaling in neoplastic cells under immunogenic chemotherapy and/or RT. In this review, we summarize the preclinical and clinical development of the combination of immunotherapy and RT in cancer therapy and highlight the latest progress in nanotechnology for augmenting the anticancer effects of immunotherapy and RT. The underlying mechanisms of nanomaterial-triggered autophagy in tumor cells and the TME are discussed in depth. Finally, we suggest the implications of these three strategies combined together to achieve the goal of maximizing the therapeutic advantages of cancer therapy and show recent advances in biomarkers for tumor response in the evaluation of those therapies.

show abstract

“…Issues related to the drug molecules, such as low solubility, low permeation, susceptibility to chemical and metabolic degradation, untargeted delivery, and, consequently, low bioavailability, which are not easily solved by using conventional formulations, can be solved by incorporating them into nanosystems [ 44 , 45 , 46 , 47 ].…”

Section: Introductionmentioning

confidence: 99%

Nanosystems for Brain Targeting of Antipsychotic Drugs: An Update on the Most Promising Nanocarriers for Increased Bioavailability and Therapeutic Efficacy

et al. 2023

View full text Add to dashboard Cite

Orally administered antipsychotic drugs are the first-line treatment for psychotic disorders, such as schizophrenia and bipolar disorder. Nevertheless, adverse drug reactions jeopardize clinical outcomes, resulting in patient non-compliance. The design formulation strategies for enhancing brain drug delivery has been a major challenge, mainly due to the restrictive properties of the blood–brain barrier. However, recent pharmacokinetic and pharmacodynamic in vivo assays confirmed the advantage of the intranasal route when compared to oral and intravenous administration, as it allows direct nose-to-brain drug transport via neuronal pathways, reducing systemic side effects and maximizing therapeutic outcomes. In addition, the incorporation of antipsychotic drugs into nanosystems such as polymeric nanoparticles, polymeric mixed micelles, solid lipid nanoparticles, nanostructured lipid carriers, nanoemulsions, nanoemulgels, nanosuspensions, niosomes and spanlastics, has proven to be quite promising. The developed nanosystems, having a small and homogeneous particle size (ideal for nose-to-brain delivery), high encapsulation efficiency and good stability, resulted in improved brain bioavailability and therapeutic-like effects in animal models. Hence, although it is essential to continue research in this field, the intranasal delivery of nanosystems for the treatment of schizophrenia, bipolar disorder and other related disorders has proven to be quite promising, opening a path for future therapies with higher efficacy.

show abstract

Engineering nanosystems to overcome barriers to cancer diagnosis and treatment

Cited by 33 publications

References 291 publications

Nano Delivery of Chemotherapeutic ICD Inducers for Tumor Immunotherapy

Nano Delivery of Chemotherapeutic ICD Inducers for Tumor Immunotherapy

Nanoparticles augment the therapeutic window of RT and immunotherapy for treating cancers: pivotal role of autophagy

Nanosystems for Brain Targeting of Antipsychotic Drugs: An Update on the Most Promising Nanocarriers for Increased Bioavailability and Therapeutic Efficacy

Contact Info

Product

Resources

About